Eureka Alert
Share

DENVER -Patients with metastatic NSCLC receiving treatment at academic centers (ACs) have an increased 2-year survival compared to patients treated at community-based centers (CCs). An overall histology-dependent survival was also noted in patients with adenocarcinoma verses squamous cell carcinoma and varied by treatment facility.

Lung cancer is the most common cancer and the leading cause of cancer-related death worldwide. There are two major types of lung cancer, small cell and non-small cell lung cancer (NSCLC). Roughly 85% of diagnosed lung cancers are NSCLC with about 40% of NSCLC patients presenting with stage IV metastatic disease. Adenocarcinoma histological subtype accounts for 40% of all NSCLC and squamous cell carcinoma histological subtype accounts for roughly 30%. Treatment for metastatic NSCLC has evolved dramatically over the last two decades with an increasing focus on treatment strategies driven by histology and molecular profile of the tumor cells. With the availability of new treatment agents and molecular testing there is growing concern that oncologists at ACs may have access to resources and specialists that CCs may not have access to and that disparities in care and survival differences may exist.

A group of investigators from Duke University in the United States used the National

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD